Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 8, 2001, Pages 3853-3860

  Toft Nielsen, M B ^a,b   Madsbad, S ^a   Holst, J J ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; BODY MASS; CALCULATION; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETIC NEUROPATHY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 0034880691     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.86.8.7743     Document Type: Article

References (25)

1. Truncated glucagon-like peptide-1, an insulin-releasing hormone from the distal gut
2. Glucagon-like peptide-1 7-36: A physiologic incretin in man
3. Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man
4. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans
5. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus
6. Preserved incretin activity of glucagon-like peptide-1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
7. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide-1(7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
8. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure
9. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
10. Truncated GLP-1 (Proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
11. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients
12. Effects of subcutaneous glucagon-like peptide 1 (GLP-1[7-36 amide]) in patients with NIDDM
13. Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent-diabetes mellitus
14. Use of a biothesiometer to measure individual vibration thresholds and their variation in 519 non-diabetic subjects
15. Autonomic neuropathy. Its diagnosis and prognosis
16. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Summary and recommendations
17. Proglucagon products in plasma from non-insulin dependent diabetics and non-diabetic controls in the fasting state and following oral glucose and intravenous arginine
18. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans
19. Potential therapeutic levels of glucagon-like peptide-1 achieved in humans by a buccal tablet
20. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in the anesthetized pig
21. Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay
22. A microflourometric method for the determination of free fatty acids in plasma
23. Correct homeostasis model assesment (HOMA) evaluation using the computer program
24. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
25. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells